This is a first-in-human, phase I/II trial of the selective RET inhibitor selpercatinib (LOXO-292) in individuals with advanced solid tumors harboring RET alterations, including non-small-cell lung cancer and medullary thyroid cancer.
A report from the trial – presented at the 2018 ASCO Annual Meeting – showed that the agent has “robust” antitumor activity against RET-altered cancers.
Updated data presented at WCLC 2019 demonstrated that selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced NSCLC harboring RET fusions.
The registrational results for the cohort with RET fusion-positive lung cancer were presented at the 2019 World Conference on Lung Cancer:
Title: Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers
Presenter: Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, USA
Monday, September 9: 09:10–09:20 (Abstract PL02.08)